The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomized multicenter study

Contraception

Volumn 67, Issue 3, 2003, Pages 173-185

  Out, H J ^a   Jespersen, J ⁱ   Pabinger, I ⁱ   MacRae, K ⁱ   Crosignani, P ⁱ   Skouby, S O ⁱ   Winkler, U H ^b   Norris, L ^c   Gaspard, U ^d   David, ^d   Van Enk, A ⁱ   Van De Ende, A ^e   Mishell, D ^f   Voncken, D ^g   Klipping, C ^h   Sidelmann, J ⁱ  

^a NV ORGANON   (Netherlands)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Farma Research BV   (Netherlands)

^h Medical Investigations   (Netherlands)

ⁱ NONE

Author keywords

Desogestrel; Ethinylestradiol; Gestodene; Hemostasis; Levonorgestrel; Oral contraceptives; Progestogen

Indexed keywords

BLOOD CLOTTING FACTOR 7; DESOGESTREL; ETHINYLESTRADIOL; FIBRIN; FIBRINOGEN; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; C REACTIVE PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE FRAGMENT; PROTHROMBIN FRAGMENT 1.2;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEADACHE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MASTALGIA; NAUSEA; NORMAL HUMAN; NULLIPARA; ORAL CONTRACEPTION; PREGNANCY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; BLOOD; COMPARATIVE STUDY; METABOLISM; MULTICENTER STUDY;

ADULT; C-REACTIVE PROTEIN; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FACTOR VII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; PEPTIDE FRAGMENTS; PROGESTINS; PROTEIN S; PROTHROMBIN;

EID: 0037369726     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00476-6     Document Type: Article

References (69)

1. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet. 346:1995;1589-1593.
2. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study . Br Med J. 312:1996;83-88.
3. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
4. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Büller H.R., Vandenbroucke J.P. Enhancement by factor V Leiden mutation of deep vein thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet. 346:1995;1593-1596.
5. Lidegaard Ø, Edström B., Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception. 57:1998;291-301.
6. Farmer R.D.T., Lawrenson R.A., Thomson C.R., Kennedy J.G., Hambleton I.R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 349:1997;83-88.
7. Farmer R.D.T., Todd J.C., Lewis M.A., MacRae K.D., Williams T.J. The risk of venous thromboembolic disease among German women using oral contraceptives a database study . Contraception. 57:1998;67-70.
8. Suissa S., Blais L., Spitzer W.O., Cusson J., Lewis M.A., Heinemann L.A.J. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 56:1997;141-156.
9. Lewis M.A., Heinemann L.A.J., MacRae K.D., et al. The differential effect of oral contraceptives the impact of full exposure history . Hum Reprod. 14:1999;1493-1499.
10. Lewis M.A. The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect. Hum Reprod Update. 5:1999;707-720.
11. Suissa S., Spitzer W.O., Rainville B., Cusson J., Lewis M., Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod. 15:2000;817-821.
12. Farmer R.D.T., Lawrenson R.A., Todd J.C., Williams T.J., MacRae K.D. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK MediPlus database. Hum Reprod Update. 5:1999;688-706.
13. Todd J.C., Lawrenson R., Farmer R.D.T., Williams T.J., Leydon G.M. Venous thromboembolic disease and combined oral contraceptives a re-analysis of the MediPlus database . Hum Reprod. 14:1999;1500-1505.
14. Farmer R.D., Williams T.J., Simpson E.L., Nightingale A.L. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives analysis of General Practice Research database . Br Med J. 321:2000;477-479.
15. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables - outline of the protocol. Contraception. 59:1999;345-355.
16. Jespersen J., Bertina R.M., Haverkate F. ECAT assay procedures a manual of laboratory techniques: European concerted action on thrombosis and disabilities of the Commission of the European Communities . 1992;1-230 Kluwer, Dordrecht.
17. Jespersen J., Bertina R.M., Haverkate F. Laboratory techniques in thrombosis - a manual. Second revised edition of ECAT Assay Procedures. 1999;1-308 Kluwer Academic Publishers, Dordrecht.
18. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives a cross-over study . Thromb Haemost. 84:2000;4-8.
19. Prasad R.N.V., Koh S.C.L., Osbron A.C., Viegas M.D., Shan Ratnam S. Effect on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Thromb Hemost. 5:1999;60-70.
20. Winkler U.H., Schindler A.D., Gillain D. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate an open, randomized, parallel-group study . Int J Fertil. 40:1995;260-268.
21. Quehenberger P., Kapiotis S., Pärtan C., et al. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol. 67:1993;33-36.
22. Bloemenkamp K.W.M., Kluft C. A comparative clinical investigation of two low-dose oral contraceptives containing either 75 μg gestodene or 150 μg desogestrel combined with 20 μg EE effect on hemostasis, lipid metabolism and carbohydrate metabolism . Gynecol Endocrinol. 12:(Suppl 3):1998;S21-S30.
23. Eichinger S., Weltermann A., Philipp K., et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost. 82:1999;1232-1236.
24. Cofrancesco E., Cortellaro M., Corradi A., Ravasi F., Bertocchi F. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement. Thromb Haemost. 79:1998;509-510.
25. Corradi A., Lazzaro L., Cofrancesco E., Cortellaro M., Ravasi F., Bertocchi F. Preoperative plasma levels of prothrombin fragment 1+2 correlate with the risk of venous thrombosis after elective hip replacement. Acta Orthop Belg. 65:1999;39-43.
26. Boneu B., Bes G., Pelzer H., Sie P., Boccalon H. D-Dimers, thrombin antithrombin II complexes and prothrombin fragments 1+2 diagnostic value in clinically suspected deep vein thrombosis . Thromb Haemost. 65:1991;28-32.
27. Meijers J.C., Middeldorp S., Tekelenburg W., et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down-regulation of fibrinolysis a randomized cross-over study of two low dose oral contraceptives . Thromb Haemost. 84:2000;9-14.
28. Wells P.S., Andersen D.R. Modern approach to diagnosis in patients with suspected deep vein thrombosis. Haemostasis. 29:(Suppl 1):1999;10-20.
29. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briet E., Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS). Thromb Haemost. 71:1994;719-722.
30. Van der Meer F.J.M., Koster T., Vandenbroucke J.P., Briet E., Rosendaal F.R. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 78:1997;631-635.
31. Bertina R.M. Molecular risk factor for thrombosis. Thromb Haemost. 82:1999;601-609.
32. Winkler U.H. Effects of hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives a review . Am J Obstet Gynecol. 179:(Suppl):1998;S51-S61.
33. De Visser M.C.H., Rosendaal F.R., Bertina R.M. A reduced sensitivity for Activated Protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 93:1999;1271-1276.
34. Koster T., Rosendaal F.R., de Ronde H., Briet E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C Leiden Thrombophilia Study . Lancet. 342:1993;1503-1506.
35. Rodeghiero F., Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factor for venous thromboembolism. Ann Intern Med. 130:1999;643-650.
36. Rosing J., Tans G., Nicolaes G.A.F., et al. Oral contraceptives and venous thrombosis different sensitivities to activated protein C in women using second- and third-generation oral contraceptives . Br J Haematol. 97:1997;233-238.
37. Curvers J., Thomassen M.C.L.G.D., Nicolaes G.A.F., et al. Acquired APC resistance and oral contraceptives differences between two functional tests . Br J Haematol. 105:1999;88-94.
38. Schramm W., Heinemann L.A.J. Oral contraceptives and venous thromboembolism acquired APC resistance? (research letter) Br J Haematol. 98:1997;491.
39. Kluft C., de Maat M.P.M., Heinemann L.A.J., Spannagl M., Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet. 354:1999;832-833.
40. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C a randomised cross-over study . Lancet. 354:1999;2036-2040.
41. Heinemann L.A.J., Assmann A., Spannagl M., et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception. 58:1998;321-322.
42. Zotz R.B., Gerhardt A., Kloeckner S., Maruhn-Debowski B., Scharf R.E. A positive family history of venous thromboembolism requires an extended screening for hereditary risk factors prior to prescription of oral contraceptives. Blood. 94:(Suppl 1):1999;241a.
43. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset P.-M. Increased risk of recurrent venous thromboembolism (VTE) during hormone replacement therapy (HRT) - results of the estrogen in venous thromboembolism trial. Blood. 94:(Suppl 1):1999;649a.
44. Tans G., Curvers J., Middeldorp S., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 84:2000;15-21.
45. Heinrich J., Balleisen L., Schulte H., Assman G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Arterolscler Thromb. 14:1994;54-59.
46. Ruddock V., Meade T.W. Factor VII activity and ischaemic heart disease fatal and non-fatal events . Q J Med. 87:1994;403-406.
47. Green D., Chamberlain A., Ruth K.J., Folsom A.R., Liu K. Factor VII, cholesterol, and triglycerides. The CARDIA study. Arterioscler Thromb Vasc Biol. 17:1997;51-55.
48. Janssen M.C.H., Verbruggen B.W., Hark P.J.C., Nováková I.R.O. Factor VIIa determination compared to D-Dimer in diagnosis of DVT. Thromb Res. 86:1997;423-426.
49. Winkler U.H., Hölscher T., Schulte H., Zierleyn J.P., Collet W., Schindler A.E. Ethinylestradiol 20 versus 30 μg combined with 150 μg desogestrel a large comparative study of the effects of two low-dose oral contraceptives on the haemostatic system . Gynecol Endocrinol. 10:1996;265-271.
50. Basdevant A., Conard J., Pelissier C., et al. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception. 48:1993;193-204.
51. Cachrimanidou A.C., Hellberg D., Nilsson S., von Schoulz B., Crona N., Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 50:1994;153-165.
52. Creatsas G., Kontopoulou-Griva I., Deligeoroglou E., et al. Effects of two combined monophasic and triphasic ethinylestradiol/gestodene oral contraceptives on natural inhibitors and other hemostatic variables. Eur J Contracept Reprod Health Care. 2:1997;31-38.
53. Granata A., Sobbrio G.A., D'Arrigo F., et al. Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives. Clin Exp Obstet Gynecol. 18:1991;9-12.
54. Petersen K.R., Sidelmann J., Skouby S.O., Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol. 168:1993;32-38.
55. Quehenberger P., Loner U., Kapiotis S., et al. Increased levels of activated factor VII and plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 76:1996;729-734.
56. Winkler U.H., Schindler A.E., Endrikat J., Düsterberg B. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception. 53:1996;75-84.
57. Koster T., Rosendaal F.R., Briet E., et al. Protein C deficiency in a controlled series of unselected outpatients an infrequent but clear risk factor for thrombosis (Leiden Thrombophilia Study) . Blood. 85:1995;2756-2761.
58. Liberti G., Bertina R.M., Rosendaal F.R. Hormonal state rather than age influenced the cut-off values of protein S re-evaluation of the thrombotic risk associated with protein S deficiency . Thromb Haemost. 82:1999;1093-1096.
59. Pabinger I., Schneider B. GTH study group on natural inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 71:1994;548-552.
60. Böttiger L.E., Boman G., Eklund G., Westerholm B. Oral contraceptives and thromboembolic disease effects of lowering oestrogen content . Lancet. I:1980;1097-1101.
61. Vessey M.P. Mortality among women participating in the Oxford/Family Planning Association contraception study. Lancet. ii:1977;731-733.
62. Vessey M.P., Mant D., Smith A., Yeates D. Oral contraception and venous thromboembolism findings in a large prospective study . Br Med J. 292:1986;526.
63. Vessey MP. Epidemiological studies of lower dose oral contraceptives. Presented at the XII World Congress of Gynecology and Obstetrics. Rio de Janeiro, October 26, 1988.
64. Lidegaard O. Oral contraceptives and venous thromboembolism an epidemiological review . Eur J Contracept Reprod Health Care. 74:1996;13-20.
65. Gerstman B.B., Piper J.M., Tomia D.K., et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 133:1991;32-37.
66. Graeff H., Battis P., Hafter R., Zander J. Evaluation of hypercoagulability in users of oral contraceptives. Klin Wochenschr. 55:1977;175-179.
67. Meade T.W., Haines A.P., North W.E.R., et al. Haemostatic, lipid and blood pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet. ii:1977;948-951.
68. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 157:1987;1042-1048.
69. Melis G.B., Fruzzetti F., Nicoletti I., et al. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mcg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception. 43:1991;23-31.